Halcygen acquires Mayne Pharma unit for $15m

Halcygen acquires Mayne Pharma unit for $15m

Halcygen Pharmaceuticals (ASX:HGN) has arranged to acquire Mayne Pharma International from Hospira Australia for $15 million.

As part of the deal, Halcygen has agreed to share a portion of the unit’s earnings with Hospira, so long as certain sales targets are met, the company said.

MPI is expected to report revenues of $63.2 million and an EBITDA of $31.2 million for calendar year 2009.

Halcygen today offered its existing shareholders the opportunity to participate in a share purchase plan at a cost of 20 cents per share.

Join the CIO Australia group on LinkedIn. The group is open to CIOs, IT Directors, COOs, CTOs and senior IT managers.

Join the newsletter!


Sign up to gain exclusive access to email subscriptions, event invitations, competitions, giveaways, and much more.

Membership is free, and your security and privacy remain protected. View our privacy policy before signing up.

Error: Please check your email address.

Tags Mergers and acquisitionsHalcygenpharmaceuticals

Show Comments